Literature DB >> 21996021

Reducing inequalities with vaccines: New Zealand's MeNZB vaccine initiative to control an epidemic.

Diana Lennon1, Stewart Reid, Joanna Stewart, Catherine Jackson, Sue Crengle, Teuila Percival.   

Abstract

Disadvantaged children of Māori and Pacific origin in New Zealand carry an inequitable burden of infectious diseases, many of which are preventable, some by vaccine. Immunisation is recognised in the developing world as a cheap, effective and efficient means of reducing inequalities. The MeNZB immunisation programme delivered in 2004-2006 towards the expected natural end of a projected 15-year epidemic appears to have had an effect (difficult to prove conclusively) on reducing the disproportionate burden of meningococcal disease carried by this group of children. It was delayed by the late engagement of the New Zealand Ministry of Health, fully briefed from 1996, leading to unnecessary and potentially avoidable deaths and sequelae, many lifelong. Further, failure to adequately assess vaccine effectiveness means that the contribution of MeNZB to the observed reduction in disease, particularly in those aged less than five years, will never be reliably known. However, the MeNZB campaign has at least left a legacy: the National Immunisation Register, which should enable New Zealand to minimise the 'vaccine inverse care law' and contribute to reducing ethnic inequity in the burden of vaccine preventable diseases.
© 2011 The Authors. Journal of Paediatrics and Child Health © 2011 Paediatrics and Child Health Division (Royal Australasian College of Physicians).

Entities:  

Mesh:

Year:  2011        PMID: 21996021     DOI: 10.1111/j.1440-1754.2010.01969.x

Source DB:  PubMed          Journal:  J Paediatr Child Health        ISSN: 1034-4810            Impact factor:   1.954


  8 in total

1.  Selection of diverse strains to assess broad coverage of the bivalent FHbp meningococcal B vaccine.

Authors:  Shannon L Harris; Cuiwen Tan; John Perez; David Radley; Kathrin U Jansen; Annaliesa S Anderson; Thomas R Jones
Journal:  NPJ Vaccines       Date:  2020-01-29       Impact factor: 7.344

Review 2.  Strategies for successful designing of immunocontraceptive vaccines and recent updates in vaccine development against sexually transmitted infections - A review.

Authors:  A S Vickram; Kuldeep Dhama; S Thanigaivel; Sandip Chakraborty; K Anbarasu; Nibedita Dey; Rohini Karunakaran
Journal:  Saudi J Biol Sci       Date:  2022-01-07       Impact factor: 4.052

3.  Inequity in Timeliness of MMR Vaccination in Children Living in the Suburbs of Iranian Cities.

Authors:  Rahmatollah Jadidi; Abolfazl Mohammadbeigi; Narges Mohammadsalehi; Hossein Ansari; Ebrahim Ghaderi
Journal:  Int J Biomed Sci       Date:  2015-06

Review 4.  Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future.

Authors:  Johan Holst; Philipp Oster; Richard Arnold; Michael V Tatley; Lisbeth M Næss; Ingeborg S Aaberge; Yvonne Galloway; Anne McNicholas; Jane O'Hallahan; Einar Rosenqvist; Steven Black
Journal:  Hum Vaccin Immunother       Date:  2013-03-07       Impact factor: 3.452

5.  Respiratory syncytial virus hospitalisations among young children: a data linkage study.

Authors:  Namrata Prasad; E Claire Newbern; Adrian A Trenholme; Tim Wood; Mark G Thompson; Nayyereh Aminisani; Q Sue Huang; Cameron C Grant
Journal:  Epidemiol Infect       Date:  2019-01       Impact factor: 2.451

6.  Selection of diverse strains to assess broad coverage of the bivalent FHbp meningococcal B vaccine.

Authors:  Shannon L Harris; Cuiwen Tan; John Perez; David Radley; Kathrin U Jansen; Annaliesa S Anderson; Thomas R Jones
Journal:  NPJ Vaccines       Date:  2020-01-29       Impact factor: 7.344

7.  The views of New Zealand general practitioners and patients on a proposed risk assessment and communication tool: a qualitative study using Normalisation Process Theory.

Authors:  Sharon Leitch; Alesha Smith; Sue Crengle; Tim Stokes
Journal:  Implement Sci Commun       Date:  2021-02-10

Review 8.  Meningococcal serogroup B vaccines: Estimating breadth of coverage.

Authors:  Robert G K Donald; Julio Cesar Hawkins; Li Hao; Paul Liberator; Thomas R Jones; Shannon L Harris; John L Perez; Joseph J Eiden; Kathrin U Jansen; Annaliesa S Anderson
Journal:  Hum Vaccin Immunother       Date:  2016-12-14       Impact factor: 3.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.